| Dr Michael R Gantz, PHARMD, RPH | |
|
3687 Veterans Dr, Fort Harrison, MT 59636-9700 | |
| (406) 442-6410 | |
| Not Available |
| Full Name | Dr Michael R Gantz |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 3687 Veterans Dr, Fort Harrison, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619523792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PHA-PHA-LIC-55047 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael R Gantz, PHARMD, RPH 3687 Veterans Dr, Fort Harrison, MT 59636-9700 Ph: () - | Dr Michael R Gantz, PHARMD, RPH 3687 Veterans Dr, Fort Harrison, MT 59636-9700 Ph: (406) 442-6410 |
News Archive
A deadly combination of two mosquito-borne viruses may be a trigger for stroke, new research published in the The Lancet Neurology has found.
New clinical guidelines developed by an expert panel that include 100 evidence-based recommendations for optimal care of patients with hyperthyroidism and other causes of thyrotoxicosis are presented in the current issue of Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.
Imaging with the molecular imaging tracer 18F-FDOPA can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases, according to new research published in The Journal of Nuclear Medicine. Using this amino acid tracer, researchers found that physicians could accurately differentiate the two types of lesions 83 percent of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging results.
Hodgkin lymphoma survivors who received certain radiation and chemotherapy regimens were at increased risk of subsequently developing stomach cancer, according to a study by scientists at the National Cancer Institute, part of the National Institutes of Health.
Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.
› Verified 8 days ago
Kimberly Van Wyk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3687 Veterans Dr, Fort Harrison, MT 59636 Phone: 406-447-7307 | |
Mary Mikeson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3687 Veterans Dr, Fort Harrison, MT 59636 Phone: 406-447-7081 | |
Ian Fitzgerald, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3687 Veterans Dr, Fort Harrison, MT 59636 Phone: 406-461-2718 | |
Ms. Sharleen Derosier Landl, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1892 Williams, Box 190 - Pharmacy, Fort Harrison, MT 59636 Phone: 406-447-7571 | |
Mr. William David Burton, RPH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1892 Williams St., Fort Harrison, MT 59636 Phone: 406-447-7571 | |
Tamara Reagor Jost, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1892 Williams Street, Fort Harrison, MT 59636 Phone: 406-447-7571 | |
Todd Will, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1892 Williams Street, Fort Harrison, MT 59636 Phone: 406-447-7575 |